Sep 9 |
Update: RBC Raises Price Target on Regeneron Pharmaceuticals to $1,282 From $1,250, Keeps Outperform Rating
|
Sep 9 |
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
|
Sep 8 |
Regeneron Pharmaceuticals, Inc. (REGN): The Best Biotech Stock According to Hedge Funds?
|
Sep 5 |
Regeneron Pharmaceuticals, Inc. (REGN) Wells Fargo 2024 Healthcare Conference (Transcript)
|
Sep 5 |
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
|
Sep 5 |
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
|
Sep 5 |
Regeneron Pharmaceuticals, Inc. (REGN) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
|
Aug 28 |
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
Aug 27 |
Regeneron's Bispecific Antibody Obtains EC Nod for Lymphoma
|
Aug 26 |
Regeneron Stock: Valuation Now Demands More Growth
|